Molecular and cytogenetic studies performed in 305 adult acute lymphoblastic leukaemia (ALL) patients enrolled in the gimema (Gruppo Italiano Malattie EMatologiche dell'Adulto) multicentric protocols identified an E2A-PBX1 fusion and/or t(1;19) in 10 patients (3.3%). All had common ALL, were mostly CyIg+ and were CD34/CD13/CD33-. Nine patients achieved a complete remission (CR); five patients showed a haematological relapse after 7 months (median). Four patients are alive in first CR with a median follow-up of 29 months; three patients are molecularly negative. This abnormality is frequently associated with early treatment failure. E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.
E2A-PBX1 fusion in adult acute lymphoblastic leukemia: biological and clinical features / Foa, Roberto; Vitale, A; Mancini, M; Cuneo, A; Mecucci, C; Elia, L; Lombardo, R; Saglio, G; Torelli, G; Annino, L; Specchia, G; Damasio, E; Tafuri, Agostino; Mandelli, Franco. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 120:3(2003), pp. 484-487. [10.1046/j.1365-2141.2003.04113.x]
E2A-PBX1 fusion in adult acute lymphoblastic leukemia: biological and clinical features.
FOA, Roberto;TAFURI, Agostino;MANDELLI, Franco
2003
Abstract
Molecular and cytogenetic studies performed in 305 adult acute lymphoblastic leukaemia (ALL) patients enrolled in the gimema (Gruppo Italiano Malattie EMatologiche dell'Adulto) multicentric protocols identified an E2A-PBX1 fusion and/or t(1;19) in 10 patients (3.3%). All had common ALL, were mostly CyIg+ and were CD34/CD13/CD33-. Nine patients achieved a complete remission (CR); five patients showed a haematological relapse after 7 months (median). Four patients are alive in first CR with a median follow-up of 29 months; three patients are molecularly negative. This abnormality is frequently associated with early treatment failure. E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
